Riferimenti bibliografici
1. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol.
Lancet. 1993; 24;341:1103-4.
2. Howitz, K.T., K.J. Bitterman, H.Y. Cohen, et al. Small molecule activators of sirtuins extend
Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191–196.
3. Timmers, S., J. Auwerx & P. Schrauwen. The journey of resveratrol from yeast to human.
Aging 2012; 4: 146–158.
4. Jang, M., L. Cai, G.O. Udeani, et al. Cancer chemopreventive activity of resveratrol, a natural
product derived from grapes. Science 1997; 275: 218–220.
5. Center for Drug Evaluation and Research. Estimating the Maximum Safe Starting Dose in
Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug
Administration 2005, Rockville, Maryland, USA.
6. Baur, J.A. & D.A. Sinclair. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev.
Drug Discov. 2006; 5: 493–506.
7. Baur, J.A., K.J. Pearson, N.L. Price, et al. Resveratrol improves health and survival of mice on
a high-calorie diet. Nature 2006; 444: 337–342.
8. Timmers, S., E. Konings, L. Bilet, et al. Calorie restriction-like effects of 30 days of resveratrol
supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab.2011;
14: 612–622.
9. Fontana, L., L. Partridge & V.D. Longo. Extending healthy life span–from yeast to humans.
Science 2010; 328: 321–326.
10. Barger, J.L., T. Kayo, J.M. Vann, et al. A low dose of dietary resveratrol partially mimics
caloric restriction and retards aging parameters in mice. PLoS ONE 2008, 3: e2264.
11. Yoshino, J., C. Conte, L. Fontana, et al. Resveratrol supplementation does not improve
metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012; 16: 658–
664.
12.Csiszar, A., K. Smith, N. Labinskyy, et al. Resveratrol attenuates TNF-alpha-induced
activation of coronary arterial endothelial cells: role of NF-kB inhibition. Am. J. Physiol. Heart
Circ. Physiol. 2006; 291: H1694–H1699.
13. Agarwal, B., M.J. Campen, M.M. Channell, et al. Resveratrol for primary prevention of
atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int. J.
Cardiol. 2013; 5;:246-8.
14. Ghanim, H., C.L. Sia, K. Korzeniewski, et al. A resveratrol and polyphenol preparation
suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J.
Clin. Endocrinol. Metab. 2011; 96: 1409–1414.
15. Ungvari, Z., Z. Bagi, A. Feher, et al. Resveratrol confers endothelial protection via activation
of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart. Circ. Physiol. 2010; 299: H18–
H24.
16. Takahashi, S. & Y. Nakashima. Repeated and long-term treatment with physiological
concentrations of resveratrol promotes NO production in vascular endothelial cells. Br. J. Nutr.
2012; 107: 774–780.
17. Bhatt, S.R., M.F. Lokhandwala & A.A. Banday. Resveratrol prevents endothelial nitric oxide
synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive
rats. Eur. J. Pharmacol. 2011; 667: 258–264.